Skip to main content

Advertisement

SpringerLink
Log in

Triptans: over the migraine

  • Oral Communications
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Migraine is a chronic, recurrent, disabling condition that affects millions of people worldwide. Proper acute care treatment for migraineurs is based on triptans, a class of specific medications approved over 20 years ago. Triptans are serotonin (5-HT1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving to doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. Triptans are not pain medications, they are abortive migraine medications which cannot prevent migraines. In addition to migraine attacks, triptans are also helpful for cluster headaches. If they are useful in other primary headaches rather than migraine and cluster headache it is yet to be addressed. In the literature there are only limited controlled clinical data to support a migraine-selective activity for triptans. Reports are available about efficacy of triptans to stop attacks of other types of primary headache, such as tension type headache, hypnic headache and other rare forms of primary headaches. On the other hand, sumatriptan failed to treat the indomethacin-responsive primary headache disorders like chronic paroxysmal hemicrania and hemicrania continua, nor was it effective in the myofascial temporal muscle pain or in atypical facial pain. Why triptans are effective in so different types of primary headaches remain unclear. Up to date, it is not clear whether the antimigrainous activity of the triptans involves an action only in the periphery or in the CNS as well. Probably we should consider triptans as “pain killers” and not only as “migraine killers”. We clearly need additional studies on triptans as putative analgesics in well-accepted animal and clinical models of acute and chronic somatic pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mondell BE (2003) A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther 25(2):331–341

    Article  PubMed  CAS  Google Scholar 

  2. MacGregor EA (2010) Prevention and treatment of menstrual migraine. Drugs 70(14):1799–1818

    Article  PubMed  CAS  Google Scholar 

  3. Allais G, Bussone G, D’Andrea G, Moschiano F, d’Onofrio F, Valguarnera F, Manzoni GC, Grazzi L, Allais R, Benedetto C, Acuto G (2011) Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 31(2):144–151

    Article  PubMed  Google Scholar 

  4. Ashkenazi A, Schwedt T (2011) Cluster headache-acute and prophylactic therapy. Headache 51:272–286

    Article  PubMed  Google Scholar 

  5. Cady RK, Gutterman D, Saiers JA, Beach ME (1997) Responsiveness of non-IHS migraine and tension-type headache to sumatriptan. Cephalalgia 17(5):588–590

    Article  PubMed  CAS  Google Scholar 

  6. Brennum J, Kjeldsen M, Olesen J (1992) The 5-HT1-like agonist sumatriptan has a significant effect in chronic tension-type headache. Cephalalgia 12(6):375–379

    Article  PubMed  CAS  Google Scholar 

  7. Brennum J, Brinck T, Schriver L (1996) Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. Eur J Neurol 3:23–28

    Article  Google Scholar 

  8. Limmroth V, Kazarawa Z, Fritsche G, Diener H-C (1999) Headache after frequent use of serotonin agonists zolmitriptan and naratriptan. Lancet 353(9150):378

    Article  PubMed  CAS  Google Scholar 

  9. Kaube H, May A, Pfaffenrath V, Diener H-C (1994) Sumatriptan misuse in daily chronic headache. BMJ 308:1573–1574

    Article  PubMed  CAS  Google Scholar 

  10. Gsist D, Tsirpoulus I, Sindrup SH et al (1998) Inappropriate use of sumatriptan. BMJ 316:1352–1353

    Article  Google Scholar 

  11. Mathew N (1999) Headache after frequent triptan use. Lancet 353(9161):1363–1364

    Article  PubMed  CAS  Google Scholar 

  12. Dekker F, Wiendels NJ, de Valk V, van der Vliet C, Knuistingh Neven A, Assendelft WJ, Ferrari MD (2011) Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people. Cephalalgia 31(8):943–952

    Article  PubMed  CAS  Google Scholar 

  13. Theeler BJ, Erickson JC (2012) Posttraumatic headache in military personnel and veterans of the Iraq and Afghanistan conflicts. Curr Treat Options Neurol 14(1):36–49

    Article  PubMed  Google Scholar 

  14. Diener HC, Obermann M, Holle D (2012) Hypnic headache: clinical course and treatment. Curr Treat Options Neurol 14(1):15–26

    Article  PubMed  Google Scholar 

  15. Schürks M, Kastrup O, Diener HC (2006) Triptan responsive hypnic headache? Eur J Neurol 13(6):666–667

    Article  PubMed  Google Scholar 

  16. Ipekdal HI, Karadas O, Oz O, Ulas UH (2011) Can triptans safely be used for airplane headache? Neurol Sci 32(6):1165–1169

    Article  PubMed  Google Scholar 

  17. Berilgen MS, Müngen BA (2011) New type of headache, headache associated with airplane travel: preliminary diagnostic criteria and possible mechanisms of aetiopathogenesis. Cephalalgia 31(12):1266–1273

    Article  PubMed  Google Scholar 

  18. Basurto Ona X, Martínez García L, Solà I, Bonfill Cosp X et al (2011) Drug therapy for treating post-dural puncture headache. Cochrane Database Syst Rev 10(8):CD007887

    Google Scholar 

  19. Bussone G, Tullo V, d’Onofrio F, Petretta V, Curone M, Frediani F, Tonini C, Omboni S (2007) Frovatriptan for the prevention of postdural puncture headache. Cephalalgia 27(7):809–813

    Article  PubMed  CAS  Google Scholar 

  20. Hikita T, Kodama H, Kaneko S, Amakata K, Ogita K, Mochizuki D, Kaga F, Nakamoto N, Fujii Y, Kikuchi A (2011) Sumatriptan as a treatment for cyclic vomiting syndrome: a clinical trial. Cephalalgia 31(4):504–507

    Article  PubMed  Google Scholar 

  21. Russell G, Abu-Arafeh I, Symon DN (2002) Abdominal migraine: evidence for existence and treatment options. Paediatr Drugs 4(1):1–8

    PubMed  Google Scholar 

  22. Kakisaka Y, Wakusawa K, Haginoya K, Saito A, Uematsu M, Yokoyama H, Sato T, Tsuchiya S (2010) Efficacy of sumatriptan in two pediatric cases with abdominal pain-related functional gastrointestinal disorders: does the mechanism overlap that of migraine? J Child Neurol 25(2):234–237

    Article  PubMed  Google Scholar 

  23. Kanai A, Saito M, Hoka S (2006) Subcutaneous sumatriptan for refractory trigeminal neuralgia. Headache 46(4):577–582

    Article  PubMed  Google Scholar 

  24. Kanai A, Suzuki A, Osawa S, Hoka S (2006) Sumatriptan alleviates pain in patients with trigeminal neuralgia. Clin J Pain 22(8):677–680

    Article  PubMed  Google Scholar 

  25. Shimohata K, Shimohata T, Motegi R, Miyashita K (2009) Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. Headache 49(5):768–770

    Article  PubMed  Google Scholar 

  26. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675

    Article  PubMed  CAS  Google Scholar 

  27. Potrebic S, Ahn AH, Skinner K, Fields HL, Basbaum AI (2003) Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: implications for the selective antimigraine action of triptans. J Neurosci 23(34):10988–10997

    PubMed  CAS  Google Scholar 

  28. Wotherspoon G, Priestley JV (2000) Expression of the 5-HT1B receptor by subtypes of rat trigeminal ganglion cells. Neuroscience 95(2):465–471

    Article  PubMed  CAS  Google Scholar 

  29. Antonaci F, Pareja JA, Caminero AB, Sjaastad O (1998) Chronic paroxysmal hemicrania and hemicrania continua: lack of efficacy of sumatriptan. Headache 38(3):197–200

    Article  PubMed  CAS  Google Scholar 

  30. Dao TT, Lund JP, Rémillard G, Lavigne GJ (1995) Is myofascial pain of the temporal muscles relieved by oral sumatriptan? A cross-over pilot study. Pain 62(2):241–244

    Article  PubMed  CAS  Google Scholar 

  31. Harrison SD, Balawi SA, Feinmann C, Harris M (1997) Atypical facial pain: a double-blind placebo-controlled crossover pilot study of subcutaneous sumatriptan. Eur Neuropsychopharmacol 7(2):83–88

    Article  PubMed  CAS  Google Scholar 

  32. Levy D, Jakubowski M, Burstein R (2004) Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B/1D receptor agonists. Proc Natl Acad Sci USA 101(12):4274–4279

    Article  PubMed  CAS  Google Scholar 

  33. Bingham S, Davey PT, Sammons M, Raval P, Overend P, Parsons AA (2001) Inhibition of inflammation-induced thermal hypersensitivity by sumatriptan through activation of 5-HT(1B/1D) receptors. Exp Neurol 167(1):65–73

    Article  PubMed  CAS  Google Scholar 

  34. De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, Dodick DW, Vanderah TW, Dussor G, Porreca F (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325–327

    PubMed  Google Scholar 

Download references

Conflict of interest

The authors certify that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Institute of Clinical Neurophysiology, Department of Neuroscience, Azienda Ospedaliero-Universitaria “OO.RR.”, Viale L.Pinto, 1, Foggia, Italy

    D. Cologno, A. Mazzeo & B. Lecce

  2. Neurology Unit, Department of Neuroscience, Azienda Ospedaliero-Universitaria “OO.RR.”, Foggia, Italy

    C. Mundi

  3. Neurology Unit, Headache Center, S. G. Moscati, Avellino, Italy

    V. Petretta & F. d’Onofrio

  4. S. Francesco Nursing Home, Telese Terme, Benevento, Italy

    G. Casucci

Authors
  1. D. Cologno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Mazzeo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Lecce
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Mundi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Petretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Casucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. d’Onofrio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Cologno.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cologno, D., Mazzeo, A., Lecce, B. et al. Triptans: over the migraine. Neurol Sci 33 (Suppl 1), 193–198 (2012). https://doi.org/10.1007/s10072-012-1066-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-012-1066-1

Keywords

Search

Navigation